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Histone deacetylase (HDAC) enzymes work together with histone acetyltransferases (HATs) to reversibly
acetylate both histone and non-histone proteins. As a result, these enzymes are involved in regulating
chromatin structure and gene expression as well as other important cellular processes. HDACs are
validated drug targets for some types of cancer, with four HDAC inhibitors clinically approved. However,
they are also showing promise as novel drug targets for other indications, including malaria and other
parasitic diseases. In this study the in vitro activity of four anti-cancer HDAC inhibitors was examined
against parasites that cause malaria and trypanosomiasis. Three of these inhibitors, suberoylanilide
hydroxamic acid (SAHA; vorinostat®), romidepsin (Istodax®) and belinostat (Beleodaq®), are clinically
approved for the treatment of T-cell lymphoma, while the fourth, panobinostat, has recently been
approved for combination therapy use in certain patients with multiple myeloma. All HDAC inhibitors
were found to inhibit the growth of asexual-stage Plasmodium falciparum malaria parasites in the
nanomolar range (IC50 10e200 nM), while only romidepsin was active at sub-mM concentrations against
bloodstream form Trypanosoma brucei brucei parasites (IC50 35 nM). The compounds were found to have
some selectivity for malaria parasites compared with mammalian cells, but were not selective for
trypanosome parasites versus mammalian cells. All compounds caused hyperacetylation of histone and
non-histone proteins in P. falciparum asexual stage parasites and inhibited deacetylase activity in
P. falciparum nuclear extracts in addition to recombinant PfHDAC1 activity. P. falciparum histone hyper-
acetylation data indicate that HDAC inhibitors may differentially affect the acetylation proﬁles of histone
H3 and H4.
© 2015 The Authors. Published by Elsevier Ltd on behalf of Australian Society for Parasitology. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Tropical parasitic diseases result in> 1 million deaths annually
(WHO, 2008). The lack of vaccines and safe and efﬁcacious drugs
that are not hampered by parasite drug resistance is driving the
search for new therapies. Targeting regulatory processes essential
for parasite growth and development, such as protein acetylation
(Andrews et al., 2012a, 2012b; Kelly et al., 2012) and methylation
(Malmquist et al., 2012; Sundriyal et al., 2014), represents a
promising starting point for identifying new anti-parasitic drugs.
This strategy has been used successfully for other diseases, such as
certain types of cancer, where inhibitors that target lysineDiscovery, Don Young Road,
sland, Australia.
drews).
Ltd on behalf of Australian Society fdeacetylase enzymes (histone deacetylase (HDAC) inhibitors) have
been approved for clinical use (Grant et al., 2007; Campas-Moya,
2009; Thompson, 2014). HDAC inhibitors are also under investi-
gation for parasitic diseases such as malaria, trypanosomiasis,
schistosomiasis and leishmaniasis (Murray et al., 2001; Ingram and
Horn, 2002; Mai et al., 2004; Sheader et al., 2004; Azzi et al., 2009;
Dubois et al., 2009; Patil et al., 2010; Wang et al., 2010; Alonso and
Serra, 2012; Andrews et al., 2012a; Kelly et al., 2012; Carrillo et al.,
2015; Stolfa et al., 2014).
HDAC inhibitors target eukaryotic HDAC enzymes which work
together with histone acetyltransferases (HATs) to reversibly
modify the acetylation state of histone and non-histone proteins
(Khan and La Thangue, 2012). As a consequence, these enzymes
regulate chromatin structure and gene expression (De Ruijter et al.,
2003) and other important cellular processes such as cell cycle
regulation and apoptosis (Khan and La Thangue, 2012). In humanor Parasitology. This is an open access article under the CC BY-NC-ND license (http://
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2008)) and classiﬁed according to their co-factor dependency on
either zinc or NAD þ and sequence homology to yeast proteins
(reviewed in (Xu et al., 2007)). In Plasmodium falciparum, ﬁve HDAC
encoding genes have been annotated (PlasmoDB gene IDs:
PF3D7_0925700 (Pfhdac1), PF3D7_345 1472200 (Pfhdac2),
PF3D7_1008000 (Pfhdac3; Pfhda2 (Coleman et al., 2014)),
PF3D7_1328800 (Pfsir2a), and PF3D7_1451400 (Pfsir2b)
(Aurrecoechea et al., 2009)). Three of the proteins/predicted pro-
teins encoded by these genes have homology to class I (PfHDAC1)
and II (PfHDAC2 and 3) mammalian HDACs, while the remaining
two are class III HDACs, or silent information regulator 2 (SIR2)
proteins. PfSir2A and B are not essential to the growth and devel-
opment of asexual intraerythrocytic P. falciparum parasites (Freitas-
Junior et al., 2005; Tonkin et al., 2009). While less is known about
the class I/II HDAC homologues, knock-down of PfHDAC3 (PfHDA2)
inhibits asexual-stage growth and development (Coleman et al.,
2014). In T. b. brucei, four putative class I/II HDAC orthologues
(TbDAC 1e4) have been identiﬁed, with TbDAC1 and 3 being
essential in bloodstream forms of the parasite (Ingram and Horn,
2002). The crucial role these enzymes play in modulating the
acetylation state of histone proteins and gene expression (Xu et al.,
2007) makes them attractive targets for novel therapeutic inter-
vention strategies.
Several experimental HDAC inhibitors have shown promising
activity in vitro (50% inhibitory concentrations (IC50) ~0.01e0.3 mM)
and in vivo against Plasmodium parasites, with some showing high
selectivity for the parasite versus mammalian cells (reviewed in
(Andrews et al., 2012b)). In contrast, only limited literature is
available in regards to HDAC inhibitor activity against trypano-
somes, with all compounds examined to date appearing non-
selective (Ingram and Horn, 2002; Sheader et al., 2004; Wang
et al., 2010; Alonso and Serra, 2012; Kelly et al., 2012; Carrillo
et al., 2015). In this study we adopted a “piggyback” approach
(Nwaka and Hudson, 2006) to extend these ﬁndings, focussing on
four HDAC inhibitors (Fig. 1) that are clinically approved for cancer.
Vorinostat (SAHA; Sigma Aldrich, USA), romidepsin (FK228; Selleck
Chemicals, USA), and belinostat (Beleodaq; Spectrum Pharmaceu-
ticals, Inc., USA) have been approved for the clinical treatment of
cutaneous or peripheral T-cell lymphoma (Grant et al., 2007; Prince
and Dickinson, 2012; Thompson, 2014) and are undergoing clinicalBelinostat
Panobinostat
Fig. 1. Chemical structures of the hydroxamate HDAC inhibitors belinostat, panobitrials for various other cancers, including prostate and epithelial
ovarian cancers (Garcia-Manero et al., 2008; Modesitt et al., 2008;
Molife et al., 2010; Coifﬁer et al., 2012). Vorinostat and belinostat
are hydroxamate-based pan-inhibitors of class I and II mammalian
HDACs (Grant et al., 2007; Steele et al., 2011), while romidepsin is a
cyclic tetrapeptide pro-drug (Sandor et al., 2002; Byrd et al., 2005)
and has some HDAC isoenzyme-selectivity for class I mammalian
HDACs (Prince and Dickinson, 2012). Panobinostat (LBH-589; Sell-
eck Chemicals, USA) is a hydroxamate-based pan-HDAC inhibitor
that acts on class I, II and IV HDACs (Prince et al., 2009). Pan-
obinostat has recently been approved for combination therapy use
in certain patients with multiple myeloma (Garnock-Jones, 2015)
and is also being investigated for acute lymphocytic leukaemia and
prostate cancer (Giles et al., 2006; Rathkopf et al., 2010). While
vorinostat and panobinostat have previously been shown to inhibit
the in vitro growth of P. falciparum (IC50 ~150 nM and ~20 nM,
respectively (Patel et al., 2009)), romidepsin and belinostat have
not previously been examined for anti-malarial activity. Pan-
obinostat and belinostat have been shown to inhibit T. b. brucei
growth (IC50 1.6 mM and 2.2 mM, respectively (Carrillo et al., 2015)),
however the activity of vorinostat and romidepsin have not been
reported against this parasite species. To compare the in vitro anti-
proliferative activities of these compounds against Plasmodium and
Trypanosoma parasites and to begin to determine whether they
have differential effects in parasites, we also proﬁled them for their
effect on P. falciparum deacetylase inhibition and in situ
hyperacetylation.2. Materials and methods
2.1. Compounds
Suberoylanilide hydroxamic acid (SAHA; Sigma Aldrich, USA)
and chloroquine (chloroquine diphosphate salt; Sigma Aldrich,
USA) were prepared as 10 mM stock solutions in 100% DMSO.
Belinostat (PXD101), romidepsin (FK228) and panobinostat
(LBH589) were purchased from Selleck Chemicals and prepared as
20 mM stock solutions in 100% DMSO. Pentamidine, diminazene
aceturate and puromycin were all purchased from Sigma Aldrich
and 0.16, 9.7 and 9.2 mM stock solutions prepared in 100% DMSO.Romidepsin
Vorinostat
nostat and vorinostat and the cyclic tetrapeptide HDAC inhibitor romidepsin.
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P. falciparum 3D7 (Walliker et al., 1987) and Dd2 (Wellems
et al., 1988) parasites were cultured in vitro with Oþ human
erythrocytes in RPMI 1640 (Life Technologies) containing 10% heat
inactivated human serum and 50 mg/L hypoxanthine. Parasites
were cultured at 37 C in 5% O2 and 5% CO2 in N2. In vitro growth
inhibition assays were assessed using the [3H] hypoxanthine
incorporation method, essentially as previously described
(Andrews et al., 2008). Brieﬂy, synchronous ring-stage
P. falciparum parasitized erythrocytes (0.25% parasitemia and
2.5% haematocrit) were incubated in 96-well plates with serial
dilutions of test compounds or controls (concentrations starting
from 0.5 to 2.5 mM) for 48 h at 37 C in parasite gas mixture (5% O2,
5% CO2, and 90% N2). Following addition of [3H] hypoxanthine (0.5
mCi/well) plates were incubated as above for a further 24 h. Assays
were stopped by freezing at 20 C. [3H]-hypoxanthine incorpo-
ration was determined by harvesting cells onto glass ﬁbre ﬁlter
mats and counting using a Perkin Elmer/Wallac Trilux 1450
MicroBeta scintillation counter. Percent inhibition of growth was
compared to vehicle controls (0.5% DMSO) and 50% inhibitory
concentrations calculated using linear interpolation of inhibition
curves. Assays were carried out in triplicate wells, on three
separate occasions with data presented as mean IC50 (±standard
deviation [SD]). Chloroquine and vorinostat were used in each
assay as positive controls and an unpaired two-tailed t test was
used for statistical analysis of differences in IC50s.
2.3. T. b. brucei growth inhibition assays
T. b. brucei 427 bloodstream trypanosomeswere cultured in vitro
at 37 C in 5% CO2 with HM1-9 medium supplemented with 10%
foetal bovine serum (FBS; Thermo Scientiﬁc). Compound activity
was assessed using an Alamar blue® viability assay, as previously
described (Sykes and Avery, 2009). Brieﬂy, logarithmic phase T. b.
brucei parasites (1200 cells/ml) were added to 384-well microtitre
plates and incubated for 24 h at 37 C in 5% CO2. Parasites were
subsequently exposed to serial dilutions of test compounds at
concentrations ranging from 20.84 to 0.021 mM. Following incu-
bation for 48 h at 37 C in 5% CO2, 10 mL of 0.49 mM resazurin
(Sigma Aldrich, USA) prepared in HMI-9 mediaþ 10% FCS was
added to assay plates and incubated for a further 2 h at 37 C in 5%
CO2 followed by 22 h at room temperature. Assay plates were read
at 535 nm excitation/590 nm emission on an Envision® multiplate
reader (PerkinElmer, USA). Data was analysed and IC50 values
calculated using the software GraphPad Prism 5. Pentamidine and
diminazine aceturate were used as positive controls. T. b. brucei, the
cause causative agent of Trypanosomiasis in cattle, closely re-
sembles human infective Trypanosoma species and was used as a
model for these studies. An unpaired two-tailed t test was used for
statistical analysis.
2.4. NFF cytotoxicity assays
Neonatal foreskin ﬁbroblast (NFF) cells were cultured in RPMI
1640 media supplemented with 10% foetal calf serum and 1%
penicillin/streptomycin (Life Technologies, USA). Cells were seeded
into 96well plates (3000/well) and incubated for 24 h at 37 C in 5%
CO2. Cells were then treated with compounds in a 2-fold dilution
series with starting drug concentrations ranging from 200 mM to
10 nM. After 72 h drug exposure media was removed and plates
were washed with PBS, 50 mL of 0.4% sulforhodamine B (Sigma
Aldrich, USA) was added for 1 h prior to washing 3 times with 1%
acetic acid. After tapping dry 100 ml 10 mM Tris base (unbuffered,
pH > 9) was added to plates for a further 30min. Assay results wereread at l ¼ 564 nm in a Synergy 2 plate reader (BioTek). Three
independent assays were carried out, each in triplicate wells. IC50
concentrations were calculated using linear interpolation of inhi-
bition curves. Chloroquine and vorinostat were used in each assay
as positive controls and an unpaired two-tailed t test was used for
statistical analysis.2.5. HEK293 cytotoxicity assays
HEK293 cells were cultured in vitro in DMEM medium sup-
plemented with 10% FBS (Life Technologies) at 37 C in 5% CO2.
Cells (72,727 cells/mL) were seeded in 384-well microtitre plates
and incubated for 24 h at 37 C in 5% CO2 before being exposed to
serial dilutions of test compounds at concentrations ranging from
41.68 to 0.021 mM for 48 h at 37 C in 5% CO2. Following drug
exposure, 10 mL of 0.49 mM resazurin (Sigma Aldrich) prepared in
DMEM mediaþ 10% FCS was added to assay plates and incubated
for 5 h at 37 C in 5% CO2 and then for 19 h at room temperature.
Assay plates were read at l ¼ 535 nm excitation/590 nm emission
on an Envision® multiplate reader (PerkinElmer, USA). Data were
analysed and IC50 values calculated using the software GraphPad
Prism 5. Puromycin was included in each assay as a positive
control and an unpaired two-tailed t test was used for statistical
analysis.2.6. Protein hyperacetylation assays
Synchronous trophozoite-stage 3D7 parasites (3e5% para-
sitemia, 5% haematocrit) were incubated with 3 IC50 concentra-
tions of test compounds or controls for 3 h in a six-well plate.
Controls included vehicle only (0.05% DMSO), chloroquine as a
negative control and vorinostat as a positive HDAC inhibitor con-
trol. Parasite infected-erythrocytes were pelleted by centrifugation
and lysed with 0.15% saponin. Following centrifugation, parasite
pellets were washed extensively with 1 PBS to remove haemo-
globin and the washed pellets resuspended in 1 SDS-PAGE
loading dye. Following heat denaturation at 94 C, proteins were
analysed by SDS-PAGE and Western blot. Proteins were transferred
to PVDFmembrane andWestern blotting carried out using Odyssey
blocking buffer (Li-Cor Biosciences) according to the manufac-
turer's instructions. Anti-tetra-acetyl histone H4 (1:2000 dilution),
anti-acetyl histone H3 lysine 9 (1:1000 dilution) and anti-acetyl
histone H3 N-terminus (1:500 dilution) primary antibodies (Milli-
pore) were used with IRDye 680 goat anti-rabbit secondary anti-
body (1:10,000 dilution) (Li-Cor Biosciences). Anti-RAP2 (1:1000
dilution) primary antibody was used with IRDye 800CW goat anti-
mouse secondary antibody (1:10,000 dilution) (Li-Cor Biosciences)
as a loading control. Anti-(pan) acetyl lysine (K103) monoclonal
antibody (1:1000 dilution) (Cell Signalling Technology) was used
with IRDye 800CW goat anti-mouse secondary antibody (Li-Cor
Biosciences). All primary antibodies were incubated with the PVDF
membranes overnight at 4 C, followed by secondary antibody in-
cubation at room temperature for 45min. Membranes were imaged
using Odyssey Classic (Li-Cor Biosciences). Following analysis with
the ﬁrst antibody, PVDF membranes were stripped at room tem-
perature for 1 h in 25 mM glycine, 1% SDS, pH 2. Complete stripping
was conﬁrmed by imaging on an Odyssey Classic (Li-Cor Bio-
sciences). Membranes were then re-probed with Anti-RAP2 pri-
mary antibody as a loading control, with analysis as above.
Densitometry analysis was carried out using Image Studio Lite
Version 3.1 software. Each sample was normalised to its respective
RAP2 loading control probed and detected on the same membrane,
and results expressed as the fold change in relative density
compared to the DMSO vehicle control (with the control set to one).
J.A. Engel et al. / International Journal for Parasitology: Drugs and Drug Resistance 5 (2015) 117e1261202.7. Deacetylase activity assays
Nuclear extracts were prepared from trophozoite stage
P. falciparum 3D7 parasites using a nuclear protein extraction kit
(Merck Millipore), according to the manufacturer's instructions.
Nuclear extracts, and recombinant PfHDAC1 (Sigma Aldrich) were
assessed in deacetylase activity assays. Nuclear extracts (~0.3 mg/
ml) were incubated with different concentrations (500e0.05 nM)
of vorinostat, belinostat, panobinostat, romidepsin or trichostatin A
(TSA; as an HDAC inhibitor control) in 96-well plates. For the
PfHDAC1 deacetylase assays, PfHDAC1 (32 ng/ml) was incubated
with 1 mM vorinostat, belinostat, panobinostat, romidepsin, TSA or
vehicle only (0.5% DMSO) in 96-well plates. Ac-RGK(Ac)-AMC ﬂu-
orogenic peptide substrate (R&D Systems) was added to each well
and samples incubated at 37 C for 1 h. Activator solution was then
added, and samples incubated at room temperature for a further
10 min. Plates were then read in a Synergy 2 plate reader (BioTek;
excitation: 350e380 nm, emission: 440e460 nm) within 60 min.
HELA nuclear extracts (266.6 mg/ml) incubated with and without
1 mM TSA served as an assay control. Three independent assays
were carried out for the 3D7 nuclear extract deacetylase assay and
results are expressed as mean percent inhibition (±standard error
of the mean [SEM]). 50% inhibitory concentrations were calculated
using linear interpolation of inhibition curves with data presented
as mean IC50 (±SD). Two independent assays, each in duplicate,
were carried out for the PfHDAC1 deacetylase assay with results
expressed as percent inhibition of PfHDAC1 enzymatic activity
(±SD) compared to DMSO vehicle controls.
3. Results
3.1. In vitro activity of HDAC inhibitors against P. falciparum
asexual-stage parasites and bloodstream form T. b. brucei
The in vitro activity of HDAC inhibitors was assessed against two
protozoan parasite species; drug sensitive (3D7) and drug resistant
(Dd2) asexual P. falciparum parasites and bloodstream form T. b.
brucei 427 parasites. Romidepsin and belinostat displayed nano-
molar range activity against 3D7 and Dd2 P. falciparum lines
(Table 1; IC50 < 0.2 mM). The IC50 of romidepsin was similar to that
of vorinostat (P > 0.05) and signiﬁcantly lower for belinostat versus
vorinostat (P¼ 0.01). The IC50's of these compoundswere, however,
signiﬁcantly higher than those of panobinostat (P < 0.05). The IC50
values for vorinostat, panobinostat and the control anti-malarial
drug, chloroquine, were consistent with previously published
data (Patel et al., 2009; Sumanadasa et al., 2012). A comparison of
P. falciparum activity data (IC90) with the maximum plasma con-
centration (Cmax) achieved in human subjects following adminis-
tration of belinostat (Cmax ¼ 88.12e182.92 mM (Yeo et al., 2012)) or
panobinostat (Cmax ¼ 0.07e1.97 mM (Prince et al., 2009)) indicatesTable 1
In vitro anti-malarial plasmodial and anti-trypanosomal activity of anti-cancer HDAC inh
Compound Mammalian cell IC50 (mM) P. falciparum IC50 (m
NFF HEK 293a 3D7
Romidepsin 0.001 (±0.001) <0.005 0.09 (±0.03)
Belinostat 2.37 (±1.61) 1.42 (±0.05) 0.06 (±0.02)
Panobinostat 0.07 (±0.01) 0.18 (±0.03) 0.01 (±0.002)
Vorinostat 5.50 (±1.31) 5.17 (±0.64) 0.12 (±0.06)
Chloroquine 48.93 (±19.22) nd 0.01 (±0.002)
Pentamidine nd >0.69 nd
Diminazene aceturate nd >37 nd
a Puromycin was the positive control for the HEK293 cytotoxicity assay (IC50 797.03 n
b Selectivity Index e mammalian cell IC50/P. falciparum IC50 or T. brucei IC50. Larger vathat both of these drugs have activity against P. falciparum (IC90
belinostat 0.12 mM; IC90 panobinostat 0.01 mM) below clinically
relevant concentrations (Fig. 2). Vorinostat (human plasma
Cmax ¼ 0.43e2.98 mM (Rubin et al., 2006); P. falciparum IC90
0.24 mM) also has activity at, or below the clinically relevant range,
while the activity of romidepsin against P. falciparum (IC90 0.18 mM)
was within, but not below, the human Cmax plasma range for this
drug (Cmax ¼ 0.07e1.02 mM (Sandor et al., 2002)).
Next the activity of the anti-cancer HDAC inhibitors was tested
against T. b. brucei 427 bloodstream trypanosomes. While T. b.
brucei cannot infect primates, this species is genotypically very
similar to the two human-infecting pathogenic species and is
therefore a validated model for early phase drug discovery for
Trypanosomiasis (e.g. (Faria et al., 2015)). Of the four HDAC in-
hibitors tested, the cyclic tetrapeptide pro-drug romidepsinwas the
most active compound (Table 1; IC50 0.035 mM), having signiﬁ-
cantly lower IC50s (48e283-fold; P < 0.0001) than the other HDAC
inhibitors which all have a hydroxamate zinc binding group. Beli-
nostat, panobinostat and vorinostat were ~100-times less active
against T.b. brucei than P. falciparum parasites. The in vitro activity of
panobinostat and belinostat against T. b. brucei was similar to that
reported in a previous study (Carrillo et al., 2015). When the anti-
Trypanosomal activity (IC90) of these compounds is compared
with achievable plasma concentrations in human subjects
following administration of these drugs (Fig. 2), vorinostat (T. b.
brucei IC90 18.73 mM), panobinostat (T. b. brucei IC90 3.28 mM) and
romidepsin (T. b. brucei IC90 0.10 mM) activity was all within, or
above, the Cmax range. Only the anti-Trypanosomal activity of
belinostat (T. b. brucei; IC90 3.64 mM) fell below the Cmax range of
this drug (Fig. 2). These data comparing T. b. brucei IC90's with
published in vivo Cmax data (Fig. 2) are presented for comparison
with P. falciparum data only. For the majority of patients diagnosed
with African Trypanosomiasis, parasites are in the central nervous
system not the peripheral circulation (reviewed in (Jones and
Avery, 2013)). In addition, in this study T. b. brucei was used as an
in vitro screening model and thus additional conﬁrmatory studies
with human infecting species need to be carried out in the future.
3.2. In vitro cytotoxicity of HDAC inhibitors against mammalian cell
lines
To assess the in vitro selectivity of compounds for parasites
versus mammalian cells, cytotoxicity assays were carried out
against neonatal foreskin ﬁbroblast (NFF) cells, using the previously
published sulforhodamine B method (Skehan et al., 1990) and
against HEK293 cells using the previously published Alamar blue®
assay (Page et al., 1993). Belinostat and vorinostat demonstrated
the greatest P. falciparum-speciﬁc selectivity against NFF cells
(Table 1; SI 11e40 and 27e46, respectively). In contrast to the
P. falciparum data, none of the HDAC inhibitors tested wereibitors.
M) P. falciparum SIb T. b. brucei IC50 (mM) T. b. brucei SIb
Dd2
0.13 (±0.04) <1 0.035 (±0.01) <1
0.13 (±0.01) 11e40 2.61 (±0.21) <1
0.03 (±0.04) 2e18 1.69 (±0.24) <1
0.19 (±0.02) 27e46 9.03 (±1.81) <1
0.08 (±0.01) 612e4893 9.92 (±2.39) 5
nd nd 0.004 (±0.002) >173
nd nd 0.06 mM (±0.002) >617
M mM (±64.95)).
lues indicate greater parasite selectivity; nd, not determined.
Fig. 2. Comparison of clinically achieved plasma concentrations of HDAC inhibitors with P. falciparum and T. b. brucei in vitro activity data. The Cmax range of each compound (black
and white stripes) was compared against the IC90s of HDAC inhibitors against P. falciparum (grey bars) and T. b. brucei (white bars). The Cmax range for vorinostat, administered to
human subjects at 400 mg orally, once daily with food was 0.43e2.98 mM (Rubin et al., 2006). The Cmax range for belinostat, administered to patients at 600e1400 mg/m2 over a
30 min intravenous infusion once on days 1e5 on a 21-day cycle, was 88.12e182.92 mM (Yeo et al., 2012). The Cmax range for romidepsin, administered at 1e24.9 mg/m2 over a 4 h
intravenous infusion on days 1 and 5 of a 21-day cycle, was 0.07e1.02 mM (Sandor et al., 2002). The Cmax range for panobinostat, administered by intravenous infusion and orally
with doses ranging between 4.8 and 20 mg/m2 and 15e80 mg, respectively, was 0.07e1.97 mM (Prince et al., 2009).
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lian cells (Table 1; SI < 1).
3.3. Activity studies against P. falciparum asexual-stage parasites
In order to determine whether romidepsin, belinostat and
panobinostat cause similar biological effects on P. falciparum par-
asites as other anti-malarial HDAC inhibitors such as vorinostat
(Dow et al., 2008; Sumanadasa et al., 2012), protein hyper-
acetylation assays were carried out. Trophozoite-stage P. falciparum
3D7 parasites were treated for 3 h with ~3 IC50 concentrations of
each compound. All assays included treatments with vorinostat as
an HDAC inhibitor control, chloroquine as a negative control and
vehicle only controls (0.05% DMSO). Equivalent loading between
lanes was conﬁrmed on the same membrane, following stripping,
using a monoclonal antibody that recognises P. falciparum rhoptry
associated protein 2 (RAP2; anti-1C3) (Baldi et al., 2000). As pre-
viously observed for vorinostat (Sumanadasa et al., 2012), using
antibody that detects acetylated histone H4 (also known to cross-
react with acetylated histone H2 forms; Millipore product
manual) belinostat and romidepsin treatment caused hyper-
acetylation (Fig. 3A). In contrast treatment with panobinostat or
chloroquine did not result in hyperacetylation compared to the
vehicle control using this antibody (Fig. 3A). Vorinostat, belinostat
and romidepsin all caused a> 1.3-fold increase in acetylation signal
compared to the control (calculated as relative density, normalised
to a loading control present on the same membrane), with romi-
depsin showing the greatest effect on acetylation detected using
the anti-(tetra) acetyl H4 antibody (2.4-fold increase compared to
control; Fig. 3A). In contrast, hyperacetylation was observed for all
HDAC inhibitors using an antibody that recognises acetylation of
the histone H3 lysine 9 residue (Fig. 3B). This antibody also appears
to have some cross-reactivity, likely with another histone form.
Vorinostat and romidepsin caused a ~5e6 -fold increase in the
hyperacetylation using anti-histone H3 lysine 9 antibody as
compared with the vehicle control. In addition, all HDAC inhibitors,
except panobinostat, caused hyperacetylation using an antibodythat recognises H3 N-terminal acetylation (Fig. 3C). Vorinostat
caused a 6-fold increase in acetylation using anti-N-terminal H3
antibody compared to the vehicle control. All HDAC inhibitors also
caused hyperacetylation of a non-histone protein of ~80e90 kDa
detected using an antibody that recognises pan-acetyl lysine resi-
dues, giving a 12e27 -fold increase in relative density compared to
the control (Fig. 3D). Together these data indicate that all four HDAC
inhibitors hyperacetylate both histone and non-histone proteins in
P. falciparum, although there do appear to be differences in the
levels of acetylation observed for different histones.
To conﬁrm that these HDAC inhibitors target P. falciparum HDAC
activity, their capacity to inhibit deacetylase activity of P. falciparum
nuclear extracts and recombinant PfHDAC1 was assessed utilizing
Ac-RGK(Ac)-AMC ﬂuorogenic peptide substrate (R&D Systems;
Fig. 4 and Table 2). All HDAC inhibitors, including the hydroxamate
HDAC inhibitor assay control TSA, inhibited deacetylase activity of
parasite nuclear extracts and recombinant PfHDAC1. The calculated
IC50 of TSA, panobinostat and romidepsin was< 4 nM for deacety-
lase inhibitory activity of P. falciparum 3D7 nuclear extracts
(Table 2), while belinostat and vorinostat were less active, with IC50
values ~55e373 times higher than the other compounds (Table 2;
IC50 214.7 nM and 335.5 nM, respectively). Panobinostat, together
with the assay control TSA, inhibited ~100% of the enzymatic ac-
tivity of recombinant PfHDAC1 at 1 mM. The percentage inhibition
of vorinostat, romidepsin and belinostat ranged from 48 to 79%.
Although romidepsin had the lowest deacetylase IC50 (0.9 (±0.8)
nM) this compound showed the least inhibition of PfHDAC1
(48.3% ± 39.3%; Table 1). However, as there was variation between
experiments it is not possible to draw any conclusions about
possible positive or negative correlations from these data. Together
with the hyperacetylation assay data, these data support these anti-
cancer HDAC inhibitors as targeting PfHDAC activity in P. falciparum.
4. Discussion
Among different approaches used for anti-parasitic drug dis-
covery, the ‘piggyback’ approach, which involves using previously
Fig. 3. Hyperacetylation of P. falciparum proteins by HDAC inhibitors. Trophozoite-stage P. falciparum 3D7 parasites were treated with 3 IC50 of different HDAC inhibitors (vor-
inostat, panobinostat, belinostat or romidepsin) or controls (DMSO vehicle or chloroquine) for 3 h followed by preparation of protein lysates and Western blot analysis using rabbit
antibodies speciﬁc to tetra-acetylated H4 (A), histone H3 lysine 9 (B), histone H3 lysine acetylated N-terminus (C), or (pan) acetyl lysine (D). Each membrane was stripped and re-
probed with anti-RAP2 monoclonal antibody to allow loading on the same gel to be ascertained. Membranes were imaged using Odyssey Classic (Li-Cor Biosciences). Densitometry
analysis was performed and each sample was normalised to the RAP2 loading control. Results are expressed as the fold change in relative density compared to the control, set to
one.
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diseases, has gained greater attention in recent years (reviewed in
(Nwaka and Hudson, 2006; Caffrey and Steverding, 2008; Andrews
et al., 2014)). Piggy-backing onto drug discovery efforts for cancer
and other diseases, in particular the development of next genera-
tion compounds with targeted selectivity, is also a strategy in the
identiﬁcation of new drug leads for parasitic diseases (reviewed in
(Andrews et al., 2014)).
In this study we investigated the in vitro anti-Plasmodial and
anti-Trypanosomal activity of HDAC inhibitors that are clinically
approved, and undergoing clinical investigation, for human cancer
therapy. Vorinosat, belinostat, panobinostat and romidepsin all
exhibit in vitro growth inhibitory activity against asexual-stage
P. falciparum parasites in the nM nanomolar range. While this is
the ﬁrst report of belinostat and romidepsin having asexual stage
anti-malarial activity, panobinostat and romidepsin have recently
been shown to have activity against sexual stage P. falciparum ga-
metocytes (IC50 0.94 mM and 0.64 mM, respectively) (Sun et al.,
2014) with> 10-fold selectivity for gametocytes compared to themammalian cell line HepG2 (Sun et al., 2014). Together with data
presented here, this suggests that these two compounds can target
both asexual and gametocyte intraerythrocytic stage parasites. This
also supports our own recent ﬁnding that vorinostat and TSA target
early (IC50 1.41 mMand 0.09 mM, respectively) and late (IC50 0.81 mM
and 0.07 mM, respectively) stage gametocytes (Trenholme et al.,
2014). Combined with studies showing that exoerythrocytic (liver
stage) Plasmodium parasites are also sensitive to certain HDAC in-
hibitors (Sumanadasa et al., 2012; Hansen et al., 2014b), these data
indicate that HDAC inhibitors are a promising class of compounds
with broad-stage anti-Plasmodial activity.
Like the control HDAC inhibitor vorinostat (SI ¼ 27e46;
Table 1), belinostat and panobinostat were found to have modest
selectivity for P. falciparum compared with the mammalian cell
lines examined (SI ¼ 11e40 and 2e18, respectively; Table 1). In
comparison to the control antimalarial drug chloroquine (SI
612e4839: Table 1) this level of selectivity is low, comparable to
an early stage drug-lead. Although we are not proposing that these
anti-cancer HDAC inhibitors be used for malaria therapy per se, it
Fig. 4. Inhibition of deacetylase activity in P. falciparum nuclear extracts. The HDAC inhibitors vorinostat, belinostat, panobinostat, romidepsin and TSA were assessed for the
inhibition of deacetylase activity in nuclear extracts prepared from trophozoite-stage P. falciparum 3D7 parasites using the Ac-RGK(Ac)-AMC ﬂuorogenic peptide substrate. The
mean percent inhibition (±standard error of the mean [SEM]) for three independent assays is shown.
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within or below the clinically relevant range (Fig. 2). This is
promising in terms of future development of more potent and
parasite-selective compounds that may have improved pharma-
cokinetic proﬁles suited to malaria therapy. Thus the piggyback
approach has had value here in providing new clues to HDACTable 2
Deacetylase activity of HDAC inhibitors against P. falciparum nuclear extra
Compound P. falciparum nuclear extract IC
TSA 3.9 ± 3.4
Vorinostat 335.5 ± 145.5
Panobinostat 3.3 ± 0.7
Romidepsin 0.9 ± 0.8
Belinostat 214.7 ± 15.3
a IC50 values are mean (±SD) of three independent dose response expe
b Mean % inhibition (±SD) of two independent assays.inhibitor drug development for malaria based on existing HDAC-
targeting anti-cancer drugs.
In contrast to the ﬁndings for P. falciparum, romidepsin, the only
cyclic tetrapeptide examined in this study, was also the only HDAC
inhibitor with sub-micromolar activity against T. b. brucei blood-
stream parasite forms (IC50 0.035 mM; Table 1). Unfortunately, thiscts and recombinant PfHDAC1.
50 (nM)a PfHDAC1 % inhibition at 1 mMb
98.9 ± 1.5
59.8 ± 12.7
100 ± 0
48.3 ± 39.3
78.5 ± 4.7
riments (Fig. 4).
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Table 1). Belinostat, panobinostat and vorinostat were also found to
be non-selective for T. b. brucei parasites when compared with
activity against normal mammalian cells (Table 1). While other
studies examining the activity and selectivity of HDAC inhibitors
against Trypanosoma parasites are limited, they are generally in line
with data from the present study with compounds tested to date all
having poor selectivity for this parasite species. The cyclic tetra-
peptide HDAC inhibitor apicidin has previously been shown to have
poor and non-selective activity against Trypanosoma brucei para-
sites (Murray et al., 2001), a lack of selectivity also being observed
for P. falciparum (Darkin-Rattray et al., 1996). The only other HDAC
inhibitors tested to date, experimental hydroxamate-derived
compounds with sub-mM activity against bloodstream T. b. brucei
427 also inhibited HDACs in mammalian cells (HeLa) with similar
potency, although comments on whole cell selectivity cannot be
made as normal mammalian cell proliferationwas not investigated
(Kelly et al., 2012).
In addition to investigating the growth inhibitory activity of
HDAC inhibitors against P. falciparum, in this study we also proﬁled
their action on the parasite using three different approaches e ex-
amination of in situ hyperacetylation changes in response to com-
pound exposure (Fig. 3), inhibition of P. falciparum nuclear protein
lysates, and inhibition of recombinant PfHDAC1 (Table 2). These
studies were not conducted with Trypanosoma parasites because,
unlike P. falciparum which contains canonical histones that are
highly conserved with those of other eukaryotes (as well as four
variants; (Miao et al., 2006)), T. brucei histones are divergent, in
particular at their posttranslationally modiﬁed N-termini (Strahl
and Allis, 2000; Alsford and Horn, 2004; Mandava et al., 2007).
This means that commercial acetyl lysine antibodies, which cross-
react with P. falciparum canonical histones, cannot be used for
T. brucei. In in situ hyperacetylation assays with P. falciparum para-
sites, belinostat, panobinostat and romidepsin were shown to
hyperacetylate both histone and non-histone proteins, consistent
with previous data for other HDAC inhibitors including vorinostat
and SB939 (Sumanadasa et al., 2012; Hansen et al., 2014a). All four
HDAC inhibitors caused hyperacetylation of a ~80 kDa proteinwhen
probed with an antibody that is pan-reactive for acetylated lysines.
We have previously shown that this protein is hyperacetylated by
SAHA, SB939 and other hydroxamates (Sumanadasa et al., 2012).
Although not yet identiﬁed, the protein may be P. falciparum heat
shock protein 90 (PfHSP90) based on data showing that this protein
is detected in parasite lysate complexes treated with TSA and pro-
bed with the same antibody (Pallavi et al., 2010). Vorinostat, beli-
nostat and romidepsin all appeared to have similar proﬁles in
hyperacetylating proteins detected by histone H3 and H4 anti-
bodies, with vorinostat causing the greatest effect using anti-
histone H3 antibody (~6-fold increase in density compared to the
control). Acetylation detected by anti-(tetra) acetyl histone H4 an-
tibodies on the other hand was affected most by romidepsin, which
resulted in a 2.4-fold increase in relative density. Interestingly
panobinostat was the only HDAC inhibitor that did not show
hyperacetylation using both histone H3 and H4 antibodies in the
Western blot analysis. Panobinostat was found to cause hyper-
acetylation using an anti-histone H3 lysine 9 antibody, but did not
increase acetylation as detected by anti-histone H3 N-terminus
antibody or anti-(tetra) acetyl H4 antibody. It may be that this
compound acts differently to the otherHDACs, however although all
compounds were tested at 3 IC50 concentrations to try to
normalize effects, subtle differences in compounduptake and target
access also need to be considered. Overall these data, which
represent the ﬁrst study aimed at trying to detect differences in
acetylation proﬁles in P. falciparum in response to HDAC inhibitors,
indicate that there may be compound-speciﬁc differences in HDACinhibitor action, possibly due to the targeting of different PfHDAC
isoforms. As discussed in greater detail below, additional studies
will be required as there may also be differences in uptake and
targeting of compounds and this may also impact on mechanistic
effects.
All of the HDAC inhibitors examined in this studywere shown to
inhibit deacetylase activity in P. falciparum nuclear extracts pre-
pared from trophozoite-stage parasites. The highest inhibition was
seen for romidepsin (Table 2; IC50 0.9 nM). TSA and panobinostat
displayed similar potencies with IC50s ~3e4 nM for nuclear extract
deacetylase inhibition. Vorinostat and belinostat had the highest
P. falciparum nuclear extract deacetylase IC50s (Table 2; 335.5 nM
and 214.7 nM, respectively), ~55e394 -fold higher than those of
romidepsin, TSA, and panobinostat. Similar levels of enzyme inhi-
bition have previously been reported for these two compounds
against different human HDAC isoforms (HDAC1, 2, 3, 4, 6, 7, 8 and
9) (Khan et al., 2008). However, unlike this study where similar
P. falciparum growth inhibition was obtained (Table 1), in prolifer-
ation inhibition studies with mammalian cells, belinostat has been
shown to be up to 11-fold more active than vorinostat (Khan et al.,
2008; Andrews et al., 2012a; Sumanadasa et al., 2012; Parker et al.,
2013). While it is tempting to try to correlate the nuclear extract
deacetylase inhibition data with the P. falciparum growth inhibition
data generated in this study, differences in compound uptake, ac-
cess to cellular targets following uptake, drug stability, and varia-
tions in off-target effects will impact activity and make these direct
comparisons difﬁcult.
A major limitation of the study of P. falciparum HDACs is the lack
of availability of recombinant HDAC enzymes. Only one
P. falciparum HDAC enzyme is currently available, PfHDAC1, and its
use is compromised by high cost and poor purity. Given these
limitations the HDAC inhibitors examined in this study were tested
for activity against recombinant PfHDAC1, but at a single concen-
tration. Data generated showed that all compounds inhibited
PfHDAC1 by at least ~50% when tested at 1 mM (Table 2). As dis-
cussed above, vorinostat and panobinostat have previously been
shown to inhibit recombinant PfHDAC1 enzymatic activity with
IC50 59 nM and 1.8 nM, respectively (Patel et al., 2009). These data
indicate that this enzyme may be a target in P. falciparum parasites.
However, as other PfHDAC isoforms are not presently available, it
remains to be determined whether other HDACs are also targeted,
or differentially targeted, by the different compounds. Likewise,
while the presence of PfHDAC1 was conﬁrmed in nuclear lysates by
Western blot (data not shown) using a polyclonal anti-PfHDAC1
antibody (Trenholme et al., 2014), antibodies to the other class I/II
HDACs are not yet available so we do not know which HDAC iso-
zymes are expressed in nuclear extracts or their relative
abundance.
In summary, this study reveals that four HDAC inhibitors clini-
cally approved for the treatment of cancer have dose-dependent
anti-parasitic activity against Plasmodium and Trypanosoma para-
sites, causative agents of malaria and trypanosomiasis. Although
the proﬁle of the inhibitors examined in this study, in particular
their relatively low selectivity for parasites versusmammalian cells,
does not support their use clinically for malaria or trypanosomiasis,
our data do indicate that they may be useful starting points for
further development of new compounds that may have more
suitable anti-parasitic proﬁles. In particular, it seems that alterna-
tive approaches need to be taken to identify more parasite-selective
compounds. HDAC inhibitor mode of action studies are currently
limited by reagent availability, however, these studies are a high
priority if the activity of this class of inhibitors is to be exploited for
malaria and other parasite species. In this paper we also present
intriguing data that suggests there are differences in how different
HDAC inhibitors target HDAC enzymes in malaria parasites and that
J.A. Engel et al. / International Journal for Parasitology: Drugs and Drug Resistance 5 (2015) 117e126 125they may target different HDAC isoforms differentially. This raises
the exciting possibility of the identiﬁcation of isoenzyme selective
anti-malarial HDAC inhibitors and their development into both
stage-speciﬁc and pan-stage inhibitors of malaria parasites.Acknowledgements
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